Lalima Sharma

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM Dipeptidyl peptidase IV (DPP-IV) inhibition to modulate the incretin effect is a proven strategy to treat type 2 diabetes mellitus. The present study describes the pharmacological profile of a novel DPP-IV inhibitor RBx-0128, as an antidiabetic agent. MATERIAL AND METHODS DPP-IV assay was carried out to evaluate in vitro potency of RBx-0128 using(More)
  • 1